- Joined
- Dec 31, 2007
- Posts
- 60,814
- Reaction score
- 14,603
- Points
- 113
What you are describing is known as “product hopping.” It is a scheme in which minor changes to the original (patented) product, such as dosage per capsule, tablet, etcetera renders the reformulated product not-equivalent to the original and therefore not subject to generic substitution. By combining introduction of the reformulated product with a switch in the market (convincing physicians to prescribe the reformulated drug), pharmaceutical companies can effectively prevent generic substitution for their products and thereby thwart consumers’ access to a lower-priced generic alternatives.
We should also note that there is a price disconnect in the pharmaceutical market, because the consumer of the drug does not choose which product to purchase. The doctor makes that decision and then the consumer (or insurer) pays for the product. By preventing or limiting choices (gaming the system), the pharmaceutical companies remove competition from the marketplace; which increases their profits, reduces options for consumers, and unfairly maintains higher prices.
This is correct.
In some cases, the pharmaceutical company creates a new drug that is slightly altered- a new delivery method, a slight change in chemical structure or a combination of two existing drugs. The drug company has the option of then discontinuing production of the original drug which forces patients to take the new brand name version. It's also no coincidence that many of the physicians who prescribe the brand name are also on that CMS list of physicians who have been paid consulting fees by the drug company that makes the brand name drug.
Because patents are granted for a particular molecular structure, this creates all sorts of opportunities for drug companies to create new versions of very similar molecules that they can then obtain a second patent on.
You might have seen some ads that Vanda runs on US television for "Non 24 disorder". In some blind people, they do have issues with maintaining a 24 hour day- something that is actually called "circadian rhythm sleep disorder" (CRSD). In 2000, researchers discovered that people with CRSD, melatonin may be effective in helping normalize the 24 hour sleep-wake cycle. You can buy 100 melatonin pills for about $7 retail.
Vanda had developed a molecule that was similar to melatonin around the same time, however researchers found that the new melatonin-like molecule wasn't as effective as short-acting benzodiazepines like Ambien. Vanda decided to market their drug- now called Hetlioz- for "Non-24" and they started running television ads showing blind people. The drug company did not do studies comparing Hetlioz to melatonin- saying that they had trouble finding enough blind people with Non-24 to do a study. Other research has shown that the drug is probably not effective but the commercials continue to run on most US stations.
Hetlioz- because it is a brand name drug- costs about $5,000 per month or about $4,993 more than melatonin.


















